Navigation Links
Pharmos Completes Private Placement - Raises $1.8 Million
Date:4/21/2009

ISELIN, N.J., April 21 /PRNewswire-FirstCall/ -- Pharmos Corporation (Pink Sheets: PARS) announced today that it has completed a private placement of common stock and warrants. At the closing, the Company issued 18,000,000 shares of common stock and warrants exercisable for an additional 18,000,000 shares of common stock for an aggregate purchase price of $1,800,000. The exercise price of the warrants, which have a five-year term, is $0.12 per share.

The three purchasers were two existing investors in the Company, Venrock Associates (which is affiliated with Anthony B. Evnin, a Director of the Company) and New Enterprise Associates (which is affiliated with Charles W. Newhall, III, a Director of the Company), and a trust affiliated with Robert F. Johnston (the Company's Executive Chairman of the Board of Directors). With respect to the private placement of the securities sold, the Company relied on the exemption from registration under the Securities Act of 1933, as amended (the "Act") provided by Rule 506 under the Act, given the number of, and nature of, the investors.

In addition, Venrock Associates, New Enterprise Associates and Mr. Johnston agreed to convert at the closing the Company's 10% Convertible Debentures due November 1, 2012 held by them, comprising an aggregate of $3,000,000 in principal amount, at a conversion price of $0.275 per share. Accrued but unpaid interest on their debentures, aggregating $80,403, was also converted at the closing, at a conversion price of $0.34 per share. An aggregate of 11,145,569 shares was issued at the closing upon conversion of the principal and accrued but unpaid interest on the debentures.

The proceeds from the private placement will be used to fund completion of the ongoing Dextofisopam Phase 2b trial and company operations through 2009. If the trial is successful, this financing would also support additional efforts to negotiate a strategic partn
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Pharmos Restructures Operations in Israel
2. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
3. Pharmos Corporation Reports 2008 Third Quarter Results
4. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
5. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
6. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
7. Eligard(R) six-month formulation successfully completes European approval procedure
8. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
9. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
10. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
11. GSI Securitization Completes Merger and Domicile Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Displays & Exhibits, Inc. a division ... show exhibit building industry, announced a management change of ... Absolute Exhibits in Tustin, California.“It is very important to ... the variation in quality as offered by overseas trade ... Adduru. Mr. Adduru is the new manager of Displays ...
(Date:4/21/2015)... 2015 On April 2, 2015, Elle ... Achieve Kylie Jenner Lips With Disastrous Results,” ... themselves while attempting an at-home lip augmentation ... that creating an airlock around one’s mouth for several ... and achieve Kylie Jenner’s now famous pout. (see: goo.gl/dFQW2L) ...
(Date:4/21/2015)... 21, 2015 Top medical tourism firm, ... for their ongoing commitment to providing superior patient experiences. ... provide patients with the best possible experience for a ... and body. , Executives at Ojas Aesthetic Clinic persistently ... of — nothing about you, without you — through ...
(Date:4/21/2015)... 2015 AvePoint, the established ... today announced a new enhancement to DocAve Policy ... Office 365 Management Activity API. This integration creates a ... and take action on all events that take place ... 365 Management Activity API provides customers with greater transparency ...
(Date:4/21/2015)... 2015 Lyft has announced the ... otolaryngologists, bringing the most advanced speech-recognition technology to ... Otolaryngologists can now experience the full benefits of ... in the industry, Lyft, which offers value-added support ... , “Lyft is very excited to be able ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:Celebrity Cosmetic Surgeon Comments on Report of Teen Girls Injuring Themselves Attempting Kylie Jenner-Inspired Twitter Challenge 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2
... of two proteins in mammalian embryos prevents the development ... at the Medical College of Wisconsin, Milwaukee, has found. ... issue of Developmental Biology, was led by Stephen Duncan, ... the Medical College. , This is the first study ...
... second monoclonal antibody drug to chemotherapy looks promising for ... Clinic researchers working with the North Central Cancer Treatment ... analysis were released May 15 as part of the ... Oncology. , Researchers found that 95 percent of ...
... Shandong, China, May 16 /Xinhua-PRNewswire-FirstCall/ --,Shengtai Pharmaceutical, Inc. ... a leading manufacturer and distributor,of high-quality, pharmaceutical grade ... the three months ended March 31, 2008., ... -- Sales increased 64.8% to $20.7 million ...
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that ... presentation at two,upcoming investor conferences., Mr. Myers will ... in London at 9:30 a.m. BST (4:30 a.m. EDT) ... 2008 Mr. Myers will present at the FBR Capital,Markets ...
... China Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China ... nutraceutical industry engaged in the,development, manufacture and distribution ... products in the People,s Republic,of China ("PRC"), today ... March 31, 2008., First Quarter 2008 ...
... anti-inflammatory medication also known by the trade name Celebrex, ... proliferation measurement of precancerous lesions in the lung, according ... D. Anderson Cancer Center. This finding demonstrates the significance ... at higher risk of developing the disease. , The ...
Cached Medicine News:Health News:Medical College of Wisconsin researchers identify proteins that help develop mammalian hearts 2Health News:Adding epratuzumab to standard therapy 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 12Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3
(Date:4/21/2015)... MONROVIA, Calif. , April 21, 2015 ... developer, manufacturer and marketer of implantable lenses and delivery ... of Directors has appointed J. Steven Roush , ... total number of members on STAAR,s Board to seven.Mr. ... reporting agencies expertise, largely gained over a 39 year ...
(Date:4/21/2015)... and CAMBRIDGE, Mass. ... ( Tokyo : 4503) and Potenza ... of immuno-oncology programs, today announced an exclusive research ... is to advance a portfolio consisting of programs ... pathways, co-stimulatory signals and regulatory T cells. The ...
(Date:4/21/2015)... TOKYO , April 21, 2015 /PRNewswire/ ... conferences, has just announced Medtech Partnering Forum 2015 ... technology industry. The event, held May 28–29 in ... international medtech partnering conference in Japan ... new developments in the rapidly changing medical technology industry ...
Breaking Medicine Technology:J. Steven Roush, CPA Appointed to STAAR Surgical Board of Directors 2J. Steven Roush, CPA Appointed to STAAR Surgical Board of Directors 3Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics 2Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics 3Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 2Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 3Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 4
... Feb. 9, 2011 GeoVax Labs, Inc. (OTC Bulletin ... develops and tests innovative HIV/AIDS vaccines, announced today the ... Alabama Vaccine Research Clinic (AVRC) of the University of ... therapeutic vaccine trial. Although the GeoVax vaccines are currently ...
... The Covaris® LE220™ high performance ultra-sonicator has received ... at the LabAutomation 2011 conference in Palm Springs ... laboratory automation conference and exhibition, bringing science, technology, and ... LabAutomation are evaluated by a team of industry experts. ...
Cached Medicine Technology:GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine 2GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine 3Covaris Receives the Society for Laboratory Automation and Screening (SLAS) New Product Award at LabAutomation 2011 2
Used to introduce large devices for vascular intervention....
Used to introduce large devices for vascular intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters and other devices for intervention....
Medicine Products: